DSRV Articles
Warning-letter analysis, 483 trend reports, and regulatory intelligence for pharma quality teams. Every piece is cited, verified, and written by our Intelligence team.
12 articles published
April 2026
Chemco Warning Letter Cleaning Component Controls
title: "FDA Tied Residue, Cleaning, and Component Failures at Chemco"
2026-04-02
Contract Testing Labs Keep Exposing GMP Control Gaps
Two March 2026 FDA-linked signals point to the same problem: contract testing oversight is still being treated as a paperwork exercise instead of a release-critical control. Small quality teams should read these cases as a warning about supplier qualification, data trust, and batch disposition risk.
2026-04-04
What FDA's Data Integrity Remediation Demands Actually Reveal
When FDA's warning letters require independent assessments, patient-risk analyses, and global CAPA strategies, the agency is not just describing consequences. It is disclosing the standards it expected to find before the inspection started.
2026-04-04
Multi-Product API Facilities and the Contamination Gap FDA Finds
FDA's March 2026 warning letter to Henan Lvyuan Pharmaceutical points to a contamination control failure pattern that is structurally embedded in how most multi-product API facilities operate. The gap is not usually in the SOP. It is in the evidence.
April 2026
Usable Procedures Are Not Defensible Quality Decisions
Modern AI tools can make SOPs clearer and easier to follow. But inspectors do not cite companies for unclear formatting. They cite them for weak investigations, missing escalation logic, and decisions that cannot be traced to evidence. Usability and defensibility are different problems.
March 2026
FDA to Akums: 'Analyst Error' Is Not a Root Cause
Akums Drugs received an FDA warning letter in February 2026 for OOS investigations that invalidated failures without scientific justification. The same pattern. Again.
March 2026
FDA Just Told You Exactly What It Expects in a 483 Response
FDA's March 2026 draft guidance formalizes for the first time what the agency expects in a 483 response — executive sign-off, risk assessment for distributed product, structured CAPA tables, and a 15-business-day window that is now explicitly tied to enforcement timelines.
March 2026
Your Stability Program Was Built for a Guideline That No Longer Exists
ICH released a single 108-page document to replace the entire Q1A-F and Q5C stability guideline stack. FDA finalization begins in 2026. Most stability teams do not know which parts of their existing programs are now misaligned. Here are the five changes that will hit hardest.
March 2026
FDA Data Integrity Enforcement Is Accelerating — Here's What the Warning Letters Actually Say
Data integrity citations appeared in over 60% of pharmaceutical manufacturing warning letters in 2025. FDA is citing the systems that allowed falsification to happen unchallenged — not just the falsification itself. Here is what the enforcement record shows and what separates sites that pass from those that don't.
March 2026
ICH Q14 Analytical Procedure Development: What QA Teams Need to Know
ICH Q14 introduces a structured, science-based approach to analytical procedure development. We break down the key concepts, lifecycle management requirements, and how they align with existing Q2 and Q12 guidelines.
February 2026
Risk-Based Cleaning Validation: Applying ICH Q9 Principles in Practice
Cleaning validation remains one of the most inspection-cited areas in pharmaceutical manufacturing. This article explores how a risk-based framework under ICH Q9 Rev.1 can rationalise your validation strategy.
January 2026
FDA's Evolving Stance on Real-Time Release Testing (RTRT)
The FDA has issued new draft guidance on RTRT as part of its modernisation initiative. We examine the regulatory pathway, technical requirements, and what this means for PAT-enabled manufacturing lines.
